Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, ...

Celltrion, a major South Korean biopharmaceutical firm, said on Tuesday its two new bio-similars for bone disease treatment ...

Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug ...

South Korean biopharmaceutical giant Celltrion announced on Tuesday that its two new biosimilars for bone disease treatment have received approval from the United States Food and Drug Administration ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

SEOUL -- Forty-one ferry sailings and four flights were canceled nationwide Tuesday, anti-disaster authorities said, amid ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

SEOUL, March 4 (Yonhap) -- South Korean stocks fell for the third consecutive session Tuesday, as U.S. President Donald Trump ...

Activist shareholders have been rarely visible ahead of the shareholders' meetings of listed companies later this month, a ...